Company: CDT
Filing Date: 2025-08-14
Form Type: 10-Q/A
Source: 0001641172-25-024123
Chunk: 7

Company: CDT Equity Inc.
Filing Date: 2025-08-14
Form: 10-Q/A
Chunk 7
---
 
   (404 
  8,061 
   (425 
   (151 
   (927 
   (631 
  5,927 
  1,594 
    (18 
  1,576 
    554 
  2,130 | ) 
 ) 
 ) 
 ) 
 ) 
 ) 
 ) 
 ) 
 ) 
 ) 
 ) 
 ) 
 ) 
 ) 
 ) 
 ) 
 ) |     | 2024 
 2024 | (3,552 
      - 
      6 
      - 
    (19 
      - 
    (25 
    502 
    431 
     79 
      - 
    422 
      - 
   (153 
    (97 
     49 
      - 
 (2,357 
      - 
      - 
      - 
      - 
      - 
      - 
      - 
      - 
 (2,357 
    (27 
 (2,384 
  4,228 
  1,844 | ) 
 ) 
 ) 
 ) 
 ) 
 ) 
 ) 
 ) 
 ) |
|:-------------------------------------------------------------------------------|:----|:-----------------------------|-------:|:--|:----|:-----|-------:|:--|
| Right of Use Asset obtained in exchange for Operating Lease Liabilities        |     | $                            |      - |   |     | $    |    350 |   |
| Issuance of Common Stock Upon Exercise of Conversion Option                    |     | $                            |  4,077 |   |     | $    |      - |   |
| Supplemental Cash Disclosures                                                  |     |                              |        |   |     |      |        |   |
| Cash paid for interest                                                         |     | $                            |    170 |   |     | $    |     80 |   |

<div align='center'>The accompanying notes are an integral part of these condensed consolidated financial statements.</div>

| 4 |

<div align='center'>CDT EQUITY INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</div>

1. Nature of the Business, Basis of Presentation and Summary of Significant Accounting Policies

On August 5, 2025, Conduit Pharmaceuticals, Inc. filed an amendment to its Second Amended and Restated Certificate
of Incorporation (the “Certificate of Incorporation”), to effect a change of the